Psoriasis is an inflammatory disorder of the skin most commonly associated with red scaly plaques. The disease has a significant impact on the lives of patients and on healthcare costs. Tazarotene has been shown in clinical trials to be an effective topical therapy for psoriasis, both as monotherapy and in combination with phototherapy or topical corticosteroids. At the 59th Annual Meeting of the American Academy of Dermatology [Washington, DC, US; March 2001], researchers from the US presented the findings of their economic analysis of tazarotene plus mometasone combination therapy versus mometasone monotherapy in the treatment of stable plaque psoriasis.